FLO FLO
Company Profile ↓Company Overview
FLO (FLO) is a publicly traded company listed on with a market capitalization of $1.69B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $5.26B (+3.0% YoY); net profit $83.83M.
- Trailing 12 Months Year-on-year growth — revenue +3.0%, earnings -66.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.7%, profit CAGR -2.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.68% |
| 1 Year: | 3.00% |
Compounded Profit Growth
| 5 Years: | -2.05% |
| 1 Year: | -66.22% |
Stock Price Performance
| 1 Year: | -50.10% |
| 6 Months: | -31.15% |
| 3 Months: | -13.07% |
| 1 Month: | -14.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -2.1% CAGR over 5 years.
- Trading 52.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Oct 2013 | Dec 2013 | Jul 2014 | Oct 2014 | Jan 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Jul 2017 | Oct 2017 | Dec 2017 | Jul 2018 | Oct 2018 | Dec 2018 | Jul 2019 | Oct 2019 | Dec 2019 | Jul 2020 | Oct 2020 | Jan 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jul 2023 | Oct 2023 | Jul 2024 | Oct 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Jul 2025 | Sep 2025 | Oct 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 926.64M | 932.82M | 873.62M | 941.28M | 923.45M | 880.67M | 975.76M | 966.56M | 917.76M | 1.03B | 989.65M | 1.02B | 1.02B | 1.03B | 983.49M | - | - | - | - | - | - | - | 1.55B | 1.24B | - | 1.23B | - | 1.23B | 1.57B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 778.35M | 636.06M | - | 638.70M | - | 634.48M | 795.39M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 775.88M | 606.77M | - | 587.85M | - | 598.38M | 776.19M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 682.66M | 513.36M | - | 515.74M | - | 531.12M | 694.84M |
| Operating Income | 53.33M | - | 65.38M | 70.38M | - | 80.04M | 69.75M | - | 81.44M | 66.13M | - | 68.72M | -52.06M | - | 52.26M | 53.45M | - | 72.33M | 58.65M | - | 79.21M | 52.99M | - | 73.92M | 52.12M | - | 71.69M | 55.45M | 88.55M | -59.35M | 95.21M | 90.18M | - | 93.22M | 93.41M | 93.41M | 72.11M | 66.52M | 67.27M | 81.35M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 140.14M | 137.17M | - | 110.24M | - | -28.39M | 136.51M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.67M | 18.88M | - | 18.22M | - | 19.89M | 24.66M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.20M | 78.46M | - | 52.15M | - | -86.75M | 60.06M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.20M | 20.10M | - | 12.62M | - | -19.68M | 18.00M |
| Net Income | 33.89M | 38.52M | 42.06M | 44.60M | 28.01M | 51.76M | 43.80M | 32.25M | 51.16M | 40.22M | 13.04M | 44.74M | -33.57M | 78.53M | 45.44M | 39.63M | 20.84M | 53.09M | 43.36M | 2.22M | 57.92M | 44.35M | 55.82M | 56.36M | 38.85M | 39.32M | 53.68M | 40.53M | 63.76M | -46.73M | 66.97M | 64.98M | - | 53.00M | 58.37M | 58.37M | 39.53M | 39.53M | -67.07M | 42.05M |
| Diluted EPS | 0.16 | 0.18 | 0.20 | 0.21 | 0.13 | 0.24 | 0.21 | 0.15 | 0.24 | 0.19 | 0.06 | 0.21 | -0.16 | 0.37 | 0.21 | 0.19 | 0.10 | 0.25 | 0.20 | 0.01 | 0.27 | 0.21 | 0.26 | 0.26 | 0.18 | 0.18 | 0.25 | 0.19 | 0.30 | -0.22 | 0.32 | 0.31 | - | 0.25 | 0.28 | 0.28 | 0.19 | 0.19 | -0.32 | 0.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2009 | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.41B | 2.60B | 2.57B | 2.77B | 3.03B | 3.73B | 3.75B | 3.78B | 3.93B | 3.92B | 3.95B | 4.12B | 4.39B | 4.33B | 4.81B | 5.09B | 5.10B | 5.26B |
| Operating Income | 182.70M | 206.33M | 205.86M | 189.03M | 218.51M | 335.23M | 275.39M | 297.88M | 264.90M | 161.00M | 212.34M | 225.43M | 321.49M | 294.92M | 303.21M | 172.87M | 348.29M | 173.98M |
| Net Income | 119.23M | 130.30M | 137.05M | 123.43M | 136.12M | 230.89M | 175.74M | 189.19M | 163.78M | 150.12M | 157.16M | 164.54M | 152.32M | 206.19M | 228.39M | 123.42M | 248.12M | 83.83M |
| Diluted EPS | 1.28 | 0.94 | 0.99 | 0.60 | 0.66 | 1.09 | 0.82 | 0.89 | 0.78 | 0.71 | 0.74 | 0.78 | 0.72 | 0.97 | 1.07 | 0.58 | 1.17 | 0.40 |
| R&D Expense | - | - | - | - | - | 2.60M | 3.20M | 3.30M | 3.00M | 2.40M | 4.90M | 4.30M | 4.00M | 5.60M | 6.10M | 5.90M | 5.10M | 9.30K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Jan 2009 | Dec 2009 | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 1.35B | 1.33B | 1.55B | 2.00B | 2.50B | 2.41B | 2.84B | 2.76B | 2.66B | 2.85B | 3.18B | 3.32B | - | 3.25B | 3.31B | 3.43B | 3.40B | 4.18B | 4.18B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 804.94M | 687.71M | 656.36M | 729.09M | - |
| Cash & Equivalents | 19.98M | 19.96M | 18.95M | 18.95M | 6.75M | 7.78M | 13.28M | 8.53M | 7.52M | 14.38M | 6.41M | 5.13M | 25.31M | 11.04M | 307.48M | - | 185.87M | 165.13M | 22.53M | 5.00M | 12.10M | 12.10M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 242.31M | 270.88M | 262.69M | 299.22M | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 349.48M | 328.25M | 334.81M | 352.52M | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.87B | 2.08B | 1.99B | 2.88B | - |
| Current Liabilities | - | - | - | 221.77M | 242.77M | 268.42M | 354.96M | 327.78M | 315.55M | 403.74M | 340.62M | 393.95M | 400.34M | 528.14M | 504.11M | - | 519.92M | 564.42M | 659.15M | 548.60M | 976.16M | 976.16M |
| Long Term Debt | - | - | - | - | - | - | 610.06M | 927.39M | 767.23M | 654.48M | 808.73M | 805.09M | 974.59M | 862.78M | 960.10M | - | 890.61M | 891.84M | 1.05B | 1.02B | 1.36B | 1.36B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.19B | 1.35B | 1.36B | 2.08B | - |
| Total Equity | 664.02M | 644.05M | 728.03M | 715.95M | 795.79M | 758.97M | 858.62M | 1.08B | 1.12B | 1.24B | 1.21B | 1.25B | 1.26B | 1.26B | 1.37B | - | 1.41B | 1.44B | 1.35B | 1.41B | 1.30B | 1.30B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 228.73M | 228.73M | 228.73M | 228.73M | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2009 | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 94.87M | 236.01M | 306.05M | 134.29M | 216.88M | - | - | 335.67M | 356.56M | 297.39M | 295.89M | 366.95M | 454.46M | - | 344.61M | 360.89M | 349.35M | 412.66M | 446.20M | 446.20M |
| Investing Cash Flow | -259.26M | -89.61M | -104.30M | -237.94M | -385.44M | - | - | -469.81M | -76.71M | -35.40M | -301.81M | -97.09M | -73.99M | - | -191.44M | -151.09M | -403.81M | -172.67M | -943.15M | -943.15M |
| Financing Cash Flow | 164.37M | -147.42M | -213.95M | 104.68M | 174.05M | - | - | 141.00M | -287.82M | -263.27M | 26.09M | -284.12M | -84.04M | - | -274.78M | -222.17M | -88.15M | -257.52M | 504.05M | 504.05M |
| Capital Expenditure | -86.86M | -72.09M | -98.40M | -79.16M | -67.26M | -99.18M | -83.78M | -90.77M | -101.73M | -75.23M | -99.42M | -103.69M | -97.93M | - | -135.96M | -169.07M | -129.08M | -132.09M | -127.11M | -127.11M |
| Free Cash Flow | 8.01M | 163.92M | 207.65M | 55.13M | 149.62M | - | - | 244.90M | 254.84M | 222.16M | 196.47M | 263.27M | 356.54M | - | 208.65M | 191.82M | 220.28M | 280.58M | 319.09M | 319.09M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.37M | -142.61M | -17.52M | 7.09M | - |
| Share Buybacks | 44.07M | 40.53M | 39.18M | 26.60M | 18.73M | 8.82M | 38.92M | 6.86M | 126.30M | 2.67M | 2.49M | 7.05M | 783.00K | - | 9.51M | 34.59M | 45.80M | 22.70M | - | 5.50M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2009 | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 7.6% | 7.9% | 8.0% | 6.8% | 7.2% | 9.0% | 7.3% | 7.9% | 6.7% | 4.1% | 5.4% | 5.5% | 7.3% | 6.8% | 6.3% | 3.4% | 6.8% | 3.3% |
| Net Margin % | 4.9% | 5.0% | 5.3% | 4.5% | 4.5% | 6.2% | 4.7% | 5.0% | 4.2% | 3.8% | 4.0% | 4.0% | 3.5% | 4.8% | 4.8% | 2.4% | 4.9% | 1.6% |
| ROE % | 18.5% | 18.2% | 17.2% | 16.3% | 15.9% | 21.5% | 15.6% | 15.2% | 13.5% | 12.0% | 12.5% | 13.0% | 11.1% | 14.6% | 15.8% | 9.1% | 17.6% | 6.4% |
| ROCE % | - | 18.3% | 19.0% | 14.7% | 13.3% | 15.4% | 13.2% | 12.2% | 10.9% | 7.1% | 8.7% | 8.5% | 11.4% | 10.8% | 11.0% | 6.2% | 12.2% | 5.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FLO
Flowers Foods to Report Second Quarter 2026 Results
Flowers Foods, Inc. (NYSE: FLO) will report its second quarter 2026 financial results on Thursday, August 20, 2026, after the market close. The company will host a live question and answer webcast at 8:30 a.m. Eastern Time the next day. Acc…
BellRing Brands (BRBR) Q3 Earnings Miss Estimates
BellRing Brands (BRBR) delivered earnings and revenue surprises of -18.92% and +1.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Reports Q2 Loss, Beats Revenue Estimates
Medifast (MED) delivered earnings and revenue surprises of +58.21% and +1.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Darling Ingredients (DAR) Q2 Earnings Surpass Estimates
Darling (DAR) delivered earnings and revenue surprises of +66.21% and -4.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Nature's Own 'Sandwishes' campaign brings kids' culinary wishes to life to benefit Make-A-Wish America
Nature's Own®, the nation's No. 1 selling loaf bread brand, is launching its new "Sandwishes" campaign through its "Slice of Hope" partnership with Make-A-Wish, turning wishes into recipes to support children with critical illnesses. The in…
3 Consumer Stocks We Approach with Caution
Regarded as defensive investments, consumer staples stocks are generally safe bets in choppy markets. On the other hand, they usually underperform during bull runs, and this paradigm has rung true over the past six months as the sector’s -3…
FLO — Frequently Asked Questions
What is the current share price of FLO?
As of 2026-08-05 17:25 PDT, FLO trades at $7.39 on NASDAQ/NYSE. Its 52-week range is $6.90 to $15.42.
What is the market capitalisation of FLO?
FLO has a market capitalisation of $1.69B on NASDAQ/NYSE.
What is the P/E ratio of FLO?
FLO trades at a trailing price-to-earnings (P/E) ratio of 18.47. Its price-to-book (P/B) ratio is 1.30.
What is the return on equity (ROE) of FLO?
FLO has a return on equity (ROE) of 6.43%. Its return on capital employed (ROCE) is 5.42%.
Is FLO a good stock to buy?
This page provides a data-driven analysis of FLO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.